secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001213900-26-024952
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028
--------------------------------------------------------------------------------

- Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.
- Net proceeds extend cash runway into summer 2028; funds Phase 2 ovarian cancer trial and FDA preparation.
- Proceeds also support pivotal trial prep, companion diagnostic strategy, and potential expansion into other WNT-driven tumors.
- Stenoparib has shown durable clinical benefit; some patients on therapy >30 months in Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026024952/0001213900-26-024952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026024952/ea0280539-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer